StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
002172.SZ$3.31-2.93%
Fair $3.31+0.0%

002172.SZ

Jiangsu Aoyang Health Industry Co.ltd.

Basic Materials / ChemicalsShenzhen

$3.31

-0.10 (-2.93%)

Fairly Valued+0.0%Fair Value $3.31Fund rank 17/100 · Data gapFallback financials|
SA 14/F
F-Score: 7/9
High DebtDeclining Revenue

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 35% · confianza 10%

FCF escenarios

weak_data · normalized FCF $-20.0M · quality 13.7/100

Data gap 17/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 11/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

14/100

F

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. Debt-to-Equity ratio is 4.86, above the 2.0 threshold Revenue has declined for 2 consecutive years
Thesis & Journal · 002172.SZLocal privado en este navegador · Jiangsu Aoyang Health Industry Co.ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.5B

P/E

82.8x

↑

EV/EBITDA

21.0x

↑

ROE

23.5%

↑

Gross Margin

13.7%

↓

Debt/Equity

4.86

↑
52-Week Range$3
$3$5

TradingView lightweight chart

002172.SZ price, volumen y niveles de valoración

Último $3.310Periodo -75.3%
Fair value: $3.310

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-3.7%

FCF CAGR

—

FCF margin

-1.1%

FCF / Net income

-0.48x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.81B · net income $41.3M · FCF $-20.0M

2022-FY → 2025-FY

Gross margin

13.7%-0.2% pts

Operating margin

6.3%+2.7% pts

Net margin

2.3%+3.0% pts

FCF margin

-1.1%+10.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.81B$1.81B$2.01B$2.17B$2.02B
Net Income$41.3M$41.3M$40.6M$49.7M$-15.4M
EBITDA$151.4M$151.4M$171.9M$185.6M$137.8M
EPS0.050.050.050.06-0.02
Gross Margin13.7%13.7%13.4%13.5%13.9%
Operating Margin6.3%6.3%5.1%4.3%3.7%
Net Margin2.3%2.3%2.0%2.3%-0.8%
Balance Sheet
Debt/Equity4.864.866.7412.9932.07
Current Ratio0.610.61———
Cash Flow
Free Cash Flow$-20.0M$-20.0M$-28.2M$-9.3M$-227.0M
Returns
ROE23.5%23.5%30.2%52.9%-34.8%
Valuation
P/E82.7582.7560.8071.83—
EV/EBITDA21.0221.0216.5921.9927.89
P/B15.5415.5418.3338.0277.18
Growth & Yield
Revenue Growth-10.1%-10.1%-7.5%7.5%—
EPS Growth0.0%0.0%-16.7%400.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

80.4%

muy exigente

EPS terminal req.

$0.29

Spread vs growth

-80.4%

5Y implied EPS CAGR

48.0%

muy exigente

EPS terminal req.

$0.36

Spread vs growth

-48.0%

10Y implied EPS CAGR

27.6%

muy exigente

EPS terminal req.

$0.57

Spread vs growth

-27.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -11.5%

Total return

-11.5%

Start / end P/E

74.8x → 66.2x

EPS bridge

0.05 → 0.05

Residual

+0.0%

EPS growth+0.0%
Multiple rerating-11.5%
Dividend+0.0%
Residual / FX / buybacks / cross-term+0.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.